Boston Scientific experienced a 6% decline in stock price over the last quarter, amid a period of market uncertainty driven by new tariffs imposed by the U.S. and retaliatory measures from China, which caused volatility in global markets. Despite announcing robust fourth-quarter results with increased sales and net income, along with optimistic full-year guidance, the company's shares were not immune to the broader market downturn. The decision of board member Charles J. Dockendorff to not seek re-election did not affect the stock significantly. The absence of a share repurchase activity also reflected cautious capital allocation amid market turbulence.

Boston Scientific has 2 warning signs we think you should know about.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

The recent U.S.-China trade tensions have introduced volatility that has been felt across global markets and affected Boston Scientific's stock performance despite its strong fourth-quarter results. Over the past five years, the company's total shareholder return was 152.34%, including share price appreciation and dividends, suggesting robust long-term growth. This far exceeds the US Medical Equipment industry's 1-year return, indicating resilience against short-term market fluctuations.

The market's reaction to the news in the intro highlights concerns about the short-term impact of global market instability. However, Boston Scientific's ongoing expansion in Asia Pacific and recent strategic acquisitions suggest potential revenue growth despite these challenges. The anticipated approval of new technologies, such as FARAPULSE PFA, could enhance revenue forecasts if successful. Meanwhile, analysts project that revenue will rise by an annual average of 11.5% over the next three years, supporting optimism about long-term profitability. On April 2, 2025, the company had a share price of US$101.24, which is currently positioned at a 12.4% discount to the consensus price target of US$115.53. This suggests potential upside if the company meets projected earnings and trades at expected multiples.

Gain insights into Boston Scientific's past trends and performance with our report on the company's historical track record.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:BSX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com